Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Recruiting · NCT07529782 · Registry updated 2026-04-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-04-14 | NCT07529782 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 38 |
| Heidelberg Pharma AG | 2 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Chao-Yang Hospital, Capital Medical University | Beijing | China | 7 |
| Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Sciences | Tianjin | China | 1 |
| Qilu Hospital of Shandong University | Jinan | China | 138 |
| The First Affiliated Hospital of Soochow University | Suzhou | China | 101 |
| The first Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | China | 69 |